This is a regulatory intimation addressed to the Department of Corporate Services of BSE Limited and the Listing Department of the National Stock Exchange of India Limited.
The disclosure states that a Meeting of the Board of Directors of Suven Life Sciences Limited is scheduled to be held on Thursday, 5th November 2026. The primary purpose of this meeting is to consider and approve the unaudited Financial Results of the Company, both on a Standalone and Consolidated basis, for the quarter and half year ended 30th September 2026.
The intimation is made pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015.
In compliance with the company's Code of Conduct for Prohibition of Insider Trading, the Trading Window for dealing in the company's securities was closed for insiders effective from 1st October 2026. The Trading Window will remain closed until 48 hours after the declaration of the aforementioned unaudited Financial Results.
The letter is signed by Kandari Sangeetha Laxmi (K. Sangeetha Laxmi), who holds the designation of Company Secretary & Compliance Officer. The document was digitally signed on October 29, 2026, at 15:51:05 IST.